Dexcom (DXCM) Accumulated Expenses (2010 - 2026)

Dexcom (DXCM) has 17 years of Accumulated Expenses data on file, last reported at $121.8 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $121.8 million, up 9.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $121.8 million (up 9.93% YoY), and the FY2025 annual result was $169.2 million, up 51.07% from the prior year.
• Accumulated Expenses slipped to $121.8 million in Q1 2026 per DXCM's latest filing, from $169.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $171.0 million in Q4 2023 and troughed at $84.7 million in Q1 2022.
• A 5-year average of $123.4 million and a median of $112.7 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 34.5% in 2024, then soared 60.87% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $134.3 million in 2022, then advanced by 27.33% to $171.0 million in 2023, then sank by 34.5% to $112.0 million in 2024, then jumped by 51.07% to $169.2 million in 2025, then slipped by 28.01% to $121.8 million in 2026.
• Business Quant data shows DXCM's Accumulated Expenses at $121.8 million in Q1 2026, $169.2 million in Q4 2025, and $170.2 million in Q3 2025.